Clover Biopharmaceuticals AUS Pty
Quick facts
Marketed products
- AREXVY · Other · revenue 1500
Phase 3 pipeline
- Comirnaty Vaccine · Immunology / Infectious Disease
Comirnaty is an mRNA vaccine that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response to prevent COVID-19 infection. - CoronaVac Vaccine · Immunology / Infectious Disease
CoronaVac is an inactivated SARS-CoV-2 vaccine that stimulates the immune system to produce antibodies and cellular immunity against the virus. - Vaxzevria Vaccine · Immunology
Vaxzevria Vaccine works by stimulating the body's immune system to produce a specific response against the SARS-CoV-2 virus.
Phase 2 pipeline
Phase 1 pipeline
- Candidate vaccine, SCB-1019
- candidate vaccine, SCB-1019T
- SCB-1019T
- SCB-1022
- SCB-1033
- SCB-2019
- SCB-2019 with Alum adjuvant
- SCB-2019 with AS03 adjuvant
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: